Clin Pediatr:是否应该对长期接受曲安奈德-磺胺甲恶唑(TMP-SMZ)预防治疗的患者进行血检监测?

2020-10-04 MedSci原创 MedSci原创

对长期接受曲安奈德-磺胺甲恶唑(TMP-SMZ)预防治疗的患者进行血检监测是一种常见的做法,以预防反复尿路感染。

对长期接受曲安奈德-磺胺甲恶唑(TMP-SMZ)预防治疗的患者进行血检监测是一种常见的做法,以预防反复尿路感染

这项多中心、随机、安慰剂对照试验招募了607名年龄在2至71个月的儿童,他们在有症状的尿路感染后被诊断为膀胱输尿管反流。研究参与者接受TMP-SMZ(n = 302)或安慰剂(n = 305),并随访2年。

 

结果,在研究开始时和24个月研究结束时,测量了血清电解质(n≥370)、肌酐(n = 310)和全血细胞计数(n≥206)。治疗组和安慰剂组未发现明显的电解质、肾脏或血液学异常。研究观察到治疗组和安慰剂组的几个实验室参数的变化,这通常是生理成熟的预期。变化在年龄的正常范围内。长期使用TMP-SMX对全血细胞计数、血清电解质或肌酐没有影响。

 

综上所述,该研究结果并不支持对长期接受TMP-SMZ预防治疗的儿童进行这些实验室检查的常规监测。

 

原始出处:

 

Milan Dattaram NadkarniTej K Mattoo, et al., Laboratory Findings After Urinary Tract Infection and Antimicrobial Prophylaxis in Children With Vesicoureteral Reflux. Clin Pediatr (Phila). 2020 Mar;59(3):259-265. doi: 10.1177/0009922819898185.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1801472, encodeId=f10d18014e2c3, content=<a href='/topic/show?id=bf67e387551' target=_blank style='color:#2F92EE;'>#磺胺甲恶唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73875, encryptionId=bf67e387551, topicName=磺胺甲恶唑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Thu Nov 19 13:56:56 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728682, encodeId=307b1e28682d9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Mar 28 10:56:56 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639624, encodeId=2b66163962411, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Sep 17 20:56:56 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706082, encodeId=88811e0608273, content=<a href='/topic/show?id=9ffc6023393' target=_blank style='color:#2F92EE;'>#曲安奈德#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60233, encryptionId=9ffc6023393, topicName=曲安奈德)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6a531161088, createdName=gujh, createdTime=Fri Jan 29 01:56:56 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447046, encodeId=ca6c144e04658, content=<a href='/topic/show?id=549489135c5' target=_blank style='color:#2F92EE;'>#血检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89135, encryptionId=549489135c5, topicName=血检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc1f5300484, createdName=Luyuxie_11, createdTime=Tue Oct 06 07:56:56 CST 2020, time=2020-10-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1801472, encodeId=f10d18014e2c3, content=<a href='/topic/show?id=bf67e387551' target=_blank style='color:#2F92EE;'>#磺胺甲恶唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73875, encryptionId=bf67e387551, topicName=磺胺甲恶唑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Thu Nov 19 13:56:56 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728682, encodeId=307b1e28682d9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Mar 28 10:56:56 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639624, encodeId=2b66163962411, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Sep 17 20:56:56 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706082, encodeId=88811e0608273, content=<a href='/topic/show?id=9ffc6023393' target=_blank style='color:#2F92EE;'>#曲安奈德#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60233, encryptionId=9ffc6023393, topicName=曲安奈德)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6a531161088, createdName=gujh, createdTime=Fri Jan 29 01:56:56 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447046, encodeId=ca6c144e04658, content=<a href='/topic/show?id=549489135c5' target=_blank style='color:#2F92EE;'>#血检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89135, encryptionId=549489135c5, topicName=血检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc1f5300484, createdName=Luyuxie_11, createdTime=Tue Oct 06 07:56:56 CST 2020, time=2020-10-06, status=1, ipAttribution=)]
    2021-03-28 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=1801472, encodeId=f10d18014e2c3, content=<a href='/topic/show?id=bf67e387551' target=_blank style='color:#2F92EE;'>#磺胺甲恶唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73875, encryptionId=bf67e387551, topicName=磺胺甲恶唑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Thu Nov 19 13:56:56 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728682, encodeId=307b1e28682d9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Mar 28 10:56:56 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639624, encodeId=2b66163962411, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Sep 17 20:56:56 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706082, encodeId=88811e0608273, content=<a href='/topic/show?id=9ffc6023393' target=_blank style='color:#2F92EE;'>#曲安奈德#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60233, encryptionId=9ffc6023393, topicName=曲安奈德)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6a531161088, createdName=gujh, createdTime=Fri Jan 29 01:56:56 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447046, encodeId=ca6c144e04658, content=<a href='/topic/show?id=549489135c5' target=_blank style='color:#2F92EE;'>#血检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89135, encryptionId=549489135c5, topicName=血检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc1f5300484, createdName=Luyuxie_11, createdTime=Tue Oct 06 07:56:56 CST 2020, time=2020-10-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1801472, encodeId=f10d18014e2c3, content=<a href='/topic/show?id=bf67e387551' target=_blank style='color:#2F92EE;'>#磺胺甲恶唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73875, encryptionId=bf67e387551, topicName=磺胺甲恶唑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Thu Nov 19 13:56:56 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728682, encodeId=307b1e28682d9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Mar 28 10:56:56 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639624, encodeId=2b66163962411, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Sep 17 20:56:56 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706082, encodeId=88811e0608273, content=<a href='/topic/show?id=9ffc6023393' target=_blank style='color:#2F92EE;'>#曲安奈德#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60233, encryptionId=9ffc6023393, topicName=曲安奈德)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6a531161088, createdName=gujh, createdTime=Fri Jan 29 01:56:56 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447046, encodeId=ca6c144e04658, content=<a href='/topic/show?id=549489135c5' target=_blank style='color:#2F92EE;'>#血检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89135, encryptionId=549489135c5, topicName=血检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc1f5300484, createdName=Luyuxie_11, createdTime=Tue Oct 06 07:56:56 CST 2020, time=2020-10-06, status=1, ipAttribution=)]
    2021-01-29 gujh
  5. [GetPortalCommentsPageByObjectIdResponse(id=1801472, encodeId=f10d18014e2c3, content=<a href='/topic/show?id=bf67e387551' target=_blank style='color:#2F92EE;'>#磺胺甲恶唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73875, encryptionId=bf67e387551, topicName=磺胺甲恶唑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Thu Nov 19 13:56:56 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728682, encodeId=307b1e28682d9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Mar 28 10:56:56 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639624, encodeId=2b66163962411, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Sep 17 20:56:56 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706082, encodeId=88811e0608273, content=<a href='/topic/show?id=9ffc6023393' target=_blank style='color:#2F92EE;'>#曲安奈德#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60233, encryptionId=9ffc6023393, topicName=曲安奈德)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6a531161088, createdName=gujh, createdTime=Fri Jan 29 01:56:56 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447046, encodeId=ca6c144e04658, content=<a href='/topic/show?id=549489135c5' target=_blank style='color:#2F92EE;'>#血检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89135, encryptionId=549489135c5, topicName=血检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc1f5300484, createdName=Luyuxie_11, createdTime=Tue Oct 06 07:56:56 CST 2020, time=2020-10-06, status=1, ipAttribution=)]
    2020-10-06 Luyuxie_11

相关资讯

Nat BME : 简易旋转体用于泌尿系统感染检测

在资源有限的环境中,现代实验室中使用的传统医疗设备面临着诸如电源中断、缺乏熟练专业人员、恶劣环境条件和缺乏快速数据连接等障碍。从而导致复杂的临床并发症但并非所有设备都能用于资源有限的环境,成本。

J Urol:为什么预防复发性尿路感染不会导致更少的肾脏瘢痕?

RIVUR(膀胱输尿管反流患儿随机干预)试验报告称,抗生素预防减少了复发性尿路感染,但抗生素预防与新的肾脏瘢痕减少无关。然而,最初的报道并没有详细评估复发性尿路感染、新的肾脏瘢痕和抗生素预防之间的关系

Clin Microbiol Infect:尿液提取物和布洛芬作为治疗女性非复杂性尿路感染的替代疗法

本研究旨在探究在延迟处方的同时提供对症治疗(乌韦-尿西或布洛芬)是否能缓解症状,并减少急性非并发性尿路感染(UTI)成年妇女的抗生素用量。

美国FDA批准了日本盐野义制药的Fetroja,用于复杂尿路感染患者

美国食品和药物管理局(FDA)批准了盐野义制药Shionogi的Fetroja(cefiderocol)用于特定类型复杂尿路感染(cUTI)的患者。根据药物的有限临床安全性和有效性数据,该组织批准了Fetroja用于18岁及以上,治疗选择有限或没有其他选择的患者。

Pediatr Infect Dis J:头孢西丁胺-阿维菌素治疗≥3个月至18岁儿童并发尿路感染的安全性和有效性

头孢噻啶胺-阿维菌素对成人复杂尿路感染(cUTI)有效且耐受性良好,但尚未对儿童cUTI患者进行评估。

Lancet Infect Dis:膀胱内噬菌体治疗尿路感染!

尿路感染(UTI)是最常见的微生物疾病之一,对社会造成巨大的经济负担。在抗生素耐药性不断增加的背景下,寻找UTI替代疗法是当务之急。